Literature DB >> 6770953

Adverse reactions to D-penicillamine after gold toxicity.

M J Dodd, I D Griffiths, M Thompson.   

Abstract

The incidence of adverse reactions to D-penicillamine in 155 patients with rheumatoid arthritis was analysed and compared with their history of adverse reactions to gold. Out of 125 patients who took only D-penicillamine, 45 developed side effects from the drug, whereas of 27 patients with a history of gold toxicity, 18 also reacted adversely to D-penicillamine. All patients who took D-penicillamine within six months after an adverse reaction to gold developed side effects from D-penicillamine. Fourteen patients developed similar adverse reactions to D-penicillamine and gold, and the interval between treatments in this group was significantly shorter (p less than 0.01) than in those who developed either differing adverse reactions to both drugs or no reaction to D-penicillamine after treatment with gold. An interval exceeding six months between treatment with gold and treatment with D-penicillamine in patients who have developed adverse reactions to gold apparently reduces the risk of adverse reactions to D-penicillamine.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6770953      PMCID: PMC1601680          DOI: 10.1136/bmj.280.6230.1498

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  5 in total

1.  Selective concentration and localization of gold in macrophages of synovial and other tissues during and after chrysotherapy in rheumatoid patients.

Authors:  B Vernon-Roberts; J L Doré; J D Jessop; W J Henderson
Journal:  Ann Rheum Dis       Date:  1976-12       Impact factor: 19.103

2.  Wilson's disease; new oral therapy.

Authors:  J M WALSHE
Journal:  Lancet       Date:  1956-01-07       Impact factor: 79.321

3.  Death after taking medicaments.

Authors:  R H Girdwood
Journal:  Br Med J       Date:  1974-03-16

4.  Trial comparing D-penicillamine and gold in rheumatoid arthritis. Preliminary report.

Authors:  E C Huskisson; T J Gibson; H W Balme; H Berry; H C Burry; R Grahame; F D Hart; D R Henderson; J A Wojtulewski
Journal:  Ann Rheum Dis       Date:  1974-11       Impact factor: 19.103

5.  Is penicillamine therapy in rheumatoid arthritis influenced by previous treatment with gold?

Authors:  M Webley; E N Coomes
Journal:  Br Med J       Date:  1978-07-08
  5 in total
  7 in total

1.  HLA types in patients with rheumatoid arthritis developing leucopenia after both gold and sulphasalazine treatment.

Authors:  H Bliddal; B Eiberg; P Helin; A Svejgaard
Journal:  Ann Rheum Dis       Date:  1989-07       Impact factor: 19.103

2.  Gold-induced aplastic pancytopenia: 14-month survival through multiple transfusions.

Authors:  R Reychler; T De Geeter; L A Verbruggen
Journal:  Clin Rheumatol       Date:  1986-06       Impact factor: 2.980

3.  Influence of previous gold toxicity on subsequent development of penicillamine toxicity.

Authors:  P J Smith; W R Swinburn; D R Swinson; I M Stewart
Journal:  Br Med J (Clin Res Ed)       Date:  1982 Aug 28-Sep 4

4.  Does the order of second-line treatment in rheumatoid arthritis matter?

Authors:  M M Steven; J A Hunter; R M Murdoch; H A Capell
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-09

Review 5.  Clinical pharmacokinetics of D-penicillamine.

Authors:  P Netter; B Bannwarth; P Péré; A Nicolas
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

Review 6.  The optimum management of arthropathies.

Authors:  C S Wolfe; G R Hughes
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

Review 7.  Slow-acting antirheumatic drugs. Drug interactions of clinical significance.

Authors:  R A Munro; R D Sturrock
Journal:  Drug Saf       Date:  1995-07       Impact factor: 5.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.